Dr. Nils Grosse Hokamp shares his experience of using mint Lesion™ at the University Hospital Cologne in this brief interview. He talks about how they have expanded their usage of mint Lesion™ over the years, how it has changed their clinical studies, and his view on the potential of structured data for research.
Potential of using structured data from clinical trials and routine for AI and radiomics research
Related Resources
Related Resources
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…
Mrs. Kelie Luby joins Mint Medical's team
Mrs. Kelie Luby will join Mint Medical’s team from January 2017 as new Vice President Clinical Trials Software and will be introduced at the upcoming…
Novel oncologic therapy response criteria (iRECIST and more)
Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…